Multinational pharmaceutical companies betting everything on development of new drugs

While growth of multinational pharmaceutical companies in the domestic market has lost in speed, they tend to focus on development of new drugs.

One of the outstanding companies in the trend is MSD Korea. Last year, the company, staring with approval of the COX-2 type anti-inflammatory agent ‘Arcoxia (etoricoxib)’, has operated a new drug pipeline.

Although Arcoxia has not been launched yet, ...